Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Aptorum Group ( (APM) ) is now available.
On January 21, 2026, Aptorum Group Limited filed a Form 6-K providing investors with unaudited interim condensed consolidated financial statements for the nine months ended September 30, 2025, alongside DiamiR Biosciences Corp.’s unaudited financials for the six months ended November 30, 2025 and unaudited pro forma condensed combined financial statements. The disclosure is part of the company’s ongoing process to complete its previously announced July 14, 2025 merger with DiamiR, for which Aptorum will create a Delaware merger subsidiary that will be combined into DiamiR, leaving DiamiR as a wholly owned subsidiary; by updating and incorporating both companies’ financials into existing U.S. registration statements, Aptorum is advancing the regulatory and shareholder information requirements needed for closing the transaction and giving stakeholders an early view of the combined entity’s prospective financial profile.
The most recent analyst rating on (APM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Aptorum Group stock, see the APM Stock Forecast page.
Spark’s Take on APM Stock
According to Spark, TipRanks’ AI Analyst, APM is a Neutral.
The score is driven primarily by weak financial performance (revenue down to $0, ongoing losses, and negative operating/free cash flow). Technicals add pressure with a broad downtrend and negative momentum, while valuation is constrained by a negative P/E and no dividend support. Modest leverage is a partial offset but does not outweigh the cash-burn and shrinking balance-sheet base.
To see Spark’s full report on APM stock, click here.
More about Aptorum Group
Aptorum Group Limited is a Cayman Islands-incorporated biopharmaceutical company listed in the United States, focused on discovering, developing and commercializing therapeutic and diagnostic technologies. The group operates through research and development activities and strategic investments in life sciences assets, and maintains a presence in London while pursuing growth through acquisitions such as the planned merger with U.S.-based DiamiR Biosciences Corp.
Average Trading Volume: 73,052
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.31M
For a thorough assessment of APM stock, go to TipRanks’ Stock Analysis page.